查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1942570

Clinical Oncology Next Generation Sequencing Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年来，临床肿瘤学次世代定序市场发展迅速，预计将从2025年的5.8亿美元增长到2026年的6.6亿美元，复合年增长率达13.3%。過去幾年的成長可歸因於癌症基因組研究的擴展、定序平台的普及、腫瘤臨床試驗的增加、分子診斷的日益普及以及定序成本的下降。

預計未來幾年，臨床腫瘤學次世代定序市場將快速成長，到2030年市場規模將達到10.4億美元，複合年成長率（CAGR）為12.1%。預測期內的成長要素包括：精準腫瘤學需求的不斷成長、基因組醫學投資的增加、院內定序檢查室的擴建、標靶癌症治療方法的日益普及以及定序技術的持續進步。預測期內的關鍵趨勢包括：基於NGS的腫瘤診斷方法的日益普及、伴隨診斷應用的廣泛應用、生物資訊學和數據分析的日益融合、個人化癌症治療方法的擴展以及對罕見突變檢測的日益重視。

癌症發生率的上升預計將推動臨床腫瘤學次世代定序（NGS）市場的成長。癌症是指一組疾病，其特徵是異常細胞在體內不受控制地生長和擴散。 NGS在檢測癌症中的新型和罕見突變方面發揮關鍵作用，有助於更好地了解個別腫瘤的分子基礎。例如，根據美國政府機構國家癌症研究所2024年5月發布的報告，美國約有1810萬名癌症倖存者。預計到2032年，這一數字將增加至2,250萬。到2040年，預計每年新增癌症病例將達2,990萬例，癌症相關死亡人數預計將增加至1,530萬人。因此，癌症發生率的上升是推動臨床腫瘤學次世代定序市場擴張的主要因素。

在臨床腫瘤學次世代定序(NGS) 市場中，主要企業正著力推動技術進步。這包括整合軟體加速器，從而顯著降低二次 NGS 分析所需的時間和成本，使實驗室能夠更快地產生結果，同時減少運算資源需求。這些加速器解決方案能夠實現全面的基因組分析，並提高大規模集中式實驗室和分散式診斷環境中高通量癌症基因panel的可及性。例如，2024年1月，總部位於德國的生物資訊公司QIAGEN Digital Insights宣布對其CLC Genomics Workbench Premium進行升級，整合LightSpeed技術以支援體細胞癌的二次分析。 LightSpeed加速器可在標準雲環境下，以低於0.72美元/次的成本，在約6分鐘內處理一個覆蓋度為3377倍的275基因癌症基因panel。 LightSpeed旨在以低功耗提供高性能和高精度，無需在現有CLC平台之外購買新的硬體或額外許可證。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 世界の臨床オンコロジー次世代定序市場：魅力度スコアと分析
  • 成長潛力分析、競爭評估、策略契合度評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 主要原料、資源和供應商清單
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章 全球市場趨勢與策略

  • 關鍵技術和未來趨勢
    • 生物技術、基因組學和精準醫學
    • 人工智慧（AI）和自主人工智慧
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 物聯網、智慧基礎設施和互聯生態系統
  • 主要趨勢
    • 次世代定序（NGS）ベースの腫瘍診断の採用拡大
    • 伴隨診斷應用程式的廣泛應用
    • 生物資訊與數據分析整合的進展
    • 拓展個人化癌症治療方法
    • 人們越來越關注罕見突變檢測

第5章 終端用戶產業市場分析

  • 醫院檢查室
  • 臨床研究所
  • 診斷檢查室
  • 癌症研究所
  • 學術醫療中心

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及新冠疫情對市場的影響

第7章 全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球臨床腫瘤學次世代定序市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 世界の臨床オンコロジー次世代定序市場規模、比較、成長率分析
  • 全球臨床腫瘤學次世代定序市場表現：規模與成長，2020-2025年
  • 世界の臨床オンコロジー次世代定序市場の予測：規模と成長, 2025-2030, 2035F

第8章 全球潛在市場規模（TAM）

第9章 市場細分

  • 透過技術
  • イオン半導体シーケン定序、焦磷酸測序、合成シーケン定序、リアルタイムシーケン定序、リガースィーケン定序、可逆性色素終止シーケン定序、ナノポアシーケン定序
  • 透過使用
  • 篩檢、伴隨診斷和其他診斷
  • 最終用戶
  • 病院ラボ、臨床研究機関、診断ラボ
  • 按類型細分：離子半導體定序
  • Ion Proton 系統、Ion PGM 系統、Ion S5 系統以及其他 Ion 半導體定序技術
  • 依類型進行亞片段化：焦磷酸測序
  • 454焦磷酸測序、その他の焦磷酸測序技術
  • 按類型細分：合成序列
  • イルミナ,シーケン定序技術、SOLiDシーケン定序技術、その他の合成シーケン定序技術
  • 按類型細分：即時定序
  • PacBio RS II 系統、Sequel 系統和其他即時定序技術
  • 按類型進行亞片段化：接合性定序
  • Helicos單分子定序和其他連接定序技術
  • 按類型進行亞分割：可逆染料終止定序
  • Illumina HiSeq、Illumina NextSeq 和其他可逆染料終止定序技術
  • 按類型細分：奈米孔定序
  • オックスフォードナノポアテクノロジーズ（MinION、GridION、PromethION）、その他のナノポアシーケン定序技術

第10章 區域與國家分析

  • 全球臨床腫瘤學次世代定序市場：按地區、績效和預測分類，2020-2025年、2025-2030年預測、2035年預測
  • 全球臨床腫瘤學次世代定序市場：國家/地區、績效及預測，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章 印度市場

第14章 日本市場

第15章：澳洲市場

第16章 印尼市場

第17章 韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章：西歐市場

第21章英國市場

第22章 德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章 東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章 南美洲市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 臨床オンコロジー次世代定序市場：競合情勢と市場シェア、2024年
  • 臨床腫瘤學次世代定序市場：公司估值矩陣
  • 臨床腫瘤學次世代定序市場：公司概況
    • Thermo Fisher Scientific
    • Oxford Nanopore Technologies Ltd.
    • QIAGEN NV
    • Myriad Genetics Inc.
    • Illumina Inc.

第37章：其他領先和創新企業

  • F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company（BD）, Takara Bio Inc.

第38章 全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 臨床オンコロジー次世代定序市場2030：新たな機会を提供する国
  • 臨床オンコロジー次世代定序市場2030：新たな機会を提供するセグメント
  • 臨床オンコロジー次世代定序市場2030：成長戦略
    • 基於市場趨勢的策略
    • 競爭對手策略

第41章附錄

簡介目錄
Product Code: ME5MCONG01_G26Q1

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

Tariffs are impacting the clinical oncology next generation sequencing market by increasing costs of imported sequencing instruments, reagents, flow cells, chips, and advanced bioinformatics hardware. Hospital laboratories and research institutions in North America and Europe are most affected due to reliance on imported sequencing platforms, while Asia-Pacific faces cost pressure on instrument manufacturing and reagent supply. These tariffs are raising operational costs and slowing technology upgrades. However, they are also encouraging regional production of sequencing consumables, domestic instrument assembly, and development of localized genomic analysis solutions.

The clinical oncology next generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next generation sequencing market statistics, including clinical oncology next generation sequencing industry global market size, regional shares, competitors with a clinical oncology next generation sequencing market share, detailed clinical oncology next generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next generation sequencing industry. This clinical oncology next generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.58 billion in 2025 to $0.66 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to expansion of cancer genomics research, increased availability of sequencing platforms, growth in oncology clinical trials, rising adoption of molecular diagnostics, declining sequencing costs.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $1.04 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for precision oncology, rising investments in genomic medicine, expansion of hospital-based sequencing laboratories, growing use of targeted cancer therapies, continuous advancements in sequencing technologies. Major trends in the forecast period include increasing adoption of ngs-based oncology diagnostics, rising use of companion diagnostic applications, growing integration of bioinformatics and data analytics, expansion of personalized cancer treatment approaches, enhanced focus on rare mutation detection.

The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.

Major companies operating in the clinical oncology next-generation sequencing (NGS) market are emphasizing technological advancements, including the integration of software accelerators that significantly cut the time and cost associated with secondary NGS analysis, allowing laboratories to generate results more rapidly while reducing computational resource requirements. These accelerator solutions enable comprehensive genomic profiling and improve the accessibility of high-throughput cancer panels for both large centralized laboratories and decentralized diagnostic environments. For instance, in January 2024, QIAGEN Digital Insights, a Germany-based bioinformatics company, introduced an upgraded version of its CLC Genomics Workbench Premium incorporating LightSpeed technology with support for somatic cancer secondary analysis. The LightSpeed accelerator is capable of processing a 275-gene cancer panel at 3377X coverage in approximately six minutes, at a cost of less than US$0.72 per test in standard cloud settings. LightSpeed is designed to deliver high performance and accuracy with lower power consumption and does not require new hardware or additional licenses beyond the existing CLC platform.

In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.

Major companies operating in the clinical oncology next generation sequencing market are Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2025. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Oncology Next Generation Sequencing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clinical oncology next generation sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
  • 2) By Application: Screening; Companion Diagnostics; Other Diagnostics
  • 3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
  • Subsegments:
  • 1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies
  • 2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
  • 3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
  • 4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
  • 5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
  • 6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
  • 7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
  • Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.; F. Hoffmann-La Roche Ltd.; PerkinElmer Inc.; Agilent Technologies Inc.; Pacific Biosciences of California Inc.; Caris Life Sciences; Paradigm Diagnostics; GATC Biotech AG; Macrogen Inc.; DNASTAR Inc.; Exosome Diagnostics Inc.; Biomatters Ltd.; Partek Inc.; Foundation Medicine Inc.; Becton Dickinson and Company (BD); Takara Bio Inc.; Knome Inc.; Genomatix Software GmbH; CLC bio; GnuBIO Inc.; Bio-Rad Laboratories Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Sysmex Corporation; Veracyte Inc.; Zymo Research Corporation; ArcherDX Inc.; Karius Inc.; OncoDNA S.A.; Personal Genome Diagnostics Inc.; PierianDx Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Clinical Oncology Next Generation Sequencing Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Clinical Oncology Next Generation Sequencing Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Clinical Oncology Next Generation Sequencing Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Clinical Oncology Next Generation Sequencing Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Ngs-Based Oncology Diagnostics
    • 4.2.2 Rising Use Of Companion Diagnostic Applications
    • 4.2.3 Growing Integration Of Bioinformatics And Data Analytics
    • 4.2.4 Expansion Of Personalized Cancer Treatment Approaches
    • 4.2.5 Enhanced Focus On Rare Mutation Detection

5. Clinical Oncology Next Generation Sequencing Market Analysis Of End Use Industries

  • 5.1 Hospital Laboratories
  • 5.2 Clinical Research Organizations
  • 5.3 Diagnostic Laboratories
  • 5.4 Cancer Research Institutes
  • 5.5 Academic Medical Centers

6. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Clinical Oncology Next Generation Sequencing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Clinical Oncology Next Generation Sequencing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Clinical Oncology Next Generation Sequencing Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Clinical Oncology Next Generation Sequencing Market Segmentation

  • 9.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
  • 9.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Screening, Companion Diagnostics, Other Diagnostics
  • 9.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories
  • 9.4. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ion Semiconductor Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
  • 9.5. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Pyro-Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 454 Pyrosequencing, Other Pyro-Sequencing Technologies
  • 9.6. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Synthesis Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
  • 9.7. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Real Time Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
  • 9.8. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ligation Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
  • 9.9. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Reversible Dye Termination Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
  • 9.10. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Nano-Pore Sequencing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

10. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

  • 10.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

  • 11.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Clinical Oncology Next Generation Sequencing Market

  • 12.1. China Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Clinical Oncology Next Generation Sequencing Market

  • 13.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Clinical Oncology Next Generation Sequencing Market

  • 14.1. Japan Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Clinical Oncology Next Generation Sequencing Market

  • 15.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Clinical Oncology Next Generation Sequencing Market

  • 16.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Clinical Oncology Next Generation Sequencing Market

  • 17.1. South Korea Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Clinical Oncology Next Generation Sequencing Market

  • 18.1. Taiwan Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Clinical Oncology Next Generation Sequencing Market

  • 19.1. South East Asia Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Clinical Oncology Next Generation Sequencing Market

  • 20.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Clinical Oncology Next Generation Sequencing Market

  • 21.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Clinical Oncology Next Generation Sequencing Market

  • 22.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Clinical Oncology Next Generation Sequencing Market

  • 23.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Clinical Oncology Next Generation Sequencing Market

  • 24.1. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Clinical Oncology Next Generation Sequencing Market

  • 25.1. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Clinical Oncology Next Generation Sequencing Market

  • 26.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Clinical Oncology Next Generation Sequencing Market

  • 27.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Clinical Oncology Next Generation Sequencing Market

  • 28.1. North America Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Clinical Oncology Next Generation Sequencing Market

  • 29.1. USA Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Clinical Oncology Next Generation Sequencing Market

  • 30.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Clinical Oncology Next Generation Sequencing Market

  • 31.1. South America Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Clinical Oncology Next Generation Sequencing Market

  • 32.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Clinical Oncology Next Generation Sequencing Market

  • 33.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Clinical Oncology Next Generation Sequencing Market

  • 34.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Clinical Oncology Next Generation Sequencing Market Regulatory and Investment Landscape

36. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

  • 36.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Clinical Oncology Next Generation Sequencing Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Clinical Oncology Next Generation Sequencing Market Company Profiles
    • 36.3.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Clinical Oncology Next Generation Sequencing Market Other Major And Innovative Companies

  • F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc.

38. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

40. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies

  • 40.1 Clinical Oncology Next Generation Sequencing Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Clinical Oncology Next Generation Sequencing Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Clinical Oncology Next Generation Sequencing Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer